COMMUNIQUÉS West-GlobeNewswire

Liposoma Technology Strengthens Its Position as a Reference Partner for Advanced Lipid-Based Delivery Systems in Europe
23/02/2026
Bridging the Gap Between Scientific Innovation and Scalable Industrial Manufacturing Amsterdam, NORTH HOLLAND, Feb. 23, 2026 (GLOBE NEWSWIRE) -- A science-driven platform supports premium nutraceuticals, medical [...]
IBA – ACQUISITION OF OWN SHARES
23/02/2026
Louvain-la-Neuve, Belgium, February 23 rd , 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA [...]
Cylinder Health and Stonebrook Risk Solutions announce strategic partnership to strengthen digestive disease management
23/02/2026
The collaboration expands Stonebrook’s specialty ecosystem with a virtual-first digestive health center of excellence delivering coordinated care across the full spectrum of GI conditions CHICAGO, Feb. 23, 2026 (GLOBE [...]
Andrzej Lewandowski of Dempster Therapeutic Services Receives Prestigious 2026 ZocDoc Patient Choice Award
23/02/2026
Chicago, IL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Dempster Therapeutic Services is proud to announce that Andrzej Lewandowski , Speech-Language Pathologist and founder, has been honored with the 2026 ZocDoc Patient Choice [...]
EssilorLuxottica: Disclosure of transactions in own shares
23/02/2026
Disclosure of transactions in own shares Paris, France (February 23, 2026 - 6:00 pm) – In accordance with the authorization granted by the Annual Shareholders’ Meeting on April 30, 2025, EssilorLuxottica declares that [...]
EssilorLuxottica: Déclaration de transactions sur actions propres
23/02/2026
Déclaration de transactions sur actions propres Paris, France (23 février 2026, 18h00) – Conformément à l’autorisation octroyée par l’Assemblée Générale du 30 avril 2025, EssilorLuxottica déclare que du 16 février 2026 [...]
LENZ Therapeutics to Present at Upcoming Investor Conferences
23/02/2026
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ ® (aceclidine ophthalmologic solution) 1. [...]
ICU Medical to Participate in Upcoming Investor Conferences
23/02/2026
SAN CLEMENTE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the [...]
Bicara Therapeutics to Participate in Upcoming Investor Conferences
23/02/2026
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
23/02/2026
HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and [...]
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
23/02/2026
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 GLEN ALLEN, Va., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL ) (“Adial” or the [...]
Prenetics Launches IM8 Daily Ultimate Essentials PRO — A Clinical Formula with Two New Flavours
23/02/2026
Up to 733% Greater Potency Across 11 Key Nutrients, Including New Saffron Nootropic and Bioactive Vitamin Forms Two New Flavours — Mango + Passionfruit and Lemon + Orange Same Price for New and Existing Customers Full [...]
Seismic Therapeutic to Participate in Upcoming Investor Conferences
23/02/2026
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Seismic Therapeutic, Inc. , the machine learning immunology company, today announced that company management will participate in the following investor conferences: TD [...]
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
23/02/2026
MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium entered into a [...]
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
23/02/2026
DUBLIN and BRIDGEWATER, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today issued a call to [...]
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
23/02/2026
PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ [...]
BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
23/02/2026
Enhanced board oversight aligns subsidiary with disciplined capital allocation and strategic evaluation framework KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) (“ [...]
PharmAla To Supply Amsterdam UMC with LaNeo™ MDMA, Including Development of New Single-Capsule Stability Data
23/02/2026
TORONTO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
23/02/2026
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) , a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December [...]

Pages